Lexaria Bioscience Corp.
As of Oct 22, 2026, Lexaria Bioscience is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $2.99, 85.1% below its 52-week high and below its 200-day average, which is falling.
Lexaria Bioscience Corp. operates as a biotechnology company. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LEXX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LEXX among Biotechnology455th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …455 | LEXX | Stage 4 · wk 5 | 12 | −7.6% |
Lexaria Bioscience: quick answers
What stage is Lexaria Bioscience in?
As of Oct 22, 2026, Lexaria Bioscience (LEXX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean
Is Lexaria Bioscience in an uptrend?
No. Lexaria Bioscience is in a Stage 4 downtrend. It trades 67.5% below its 200-day average, which is falling.
How far is Lexaria Bioscience from its 52-week high?
Lexaria Bioscience closed at $2.99 on Oct 22, 2026, 85.1% below its 52-week high of $20.10. Its 52-week low is $2.60.
How has Lexaria Bioscience performed over the past year?
As of Oct 22, 2026, Lexaria Bioscience is down 78.0% over the past year and down 69.5% so far in 2026.
Which sector and industry is Lexaria Bioscience in?
Lexaria Bioscience is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.